DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

National Advisory Council on Migrant Health; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), notice is hereby given of the following meeting:

Name: National Advisory Council on Migrant Health.

Dates and Times: December 10, 2013, 8:00 a.m. to 5:00 p.m.

Place: Jackson Federal Building, Seattle

Status: The meeting will be open to the public.

Purpose: The purpose of the meeting is to discuss services and issues related to the health of migrant and seasonal agricultural workers and their families, and to formulate recommendations for the Secretary of Health and Human Services.

Agenda: The agenda includes an overview of the Council’s general business activities. The Council will also hear presentations from experts on agricultural worker issues, including the status of agricultural worker health at the local and national levels.

In addition, the council will be holding a public hearing at which migrant agricultural workers will have the opportunity to testify before the Council regarding matters that affect the health of migrant agricultural workers. The hearing is scheduled for Tuesday, December 10, from 1:30 p.m. to 4:30 p.m., at the Jackson Federal Building.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301–496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Surgical Tool for Ocular Tissue Transplantation

Description of Technology: The invention pertains to a device for delivering in a precise and controlled way a piece of tissue or sheet of cells into the eye such that manipulation of and damage to the tissue, cells, and eye are minimized. The device features a handle with actuating means, a stationary needle extending from the handle to the distal tip, and a pair of grasping arms at the distal tip configured for holding tissue or a sheet of cells. An outer tip needle is slidably disposed along a length the stationary needle. When the outer tip needle is disposed over the pair of grasping arms, the arms are collapsed. When the outer tip needle is withdrawn away from the grasping arms, the arms are expanded. The outer tip needle, when disposed over the grasping arms, also allows for protection of the tissue or sheet of cells during surgical manipulation.

Potential Commercial Applications:

- Ocular transplantation
- Ocular surgery

Competitive Advantages: Can perform transplantation of micron-sized tissue or cell grafts.

Development Stage: Prototype


Licensing Contact: Michael Shmilovich; 301–435–5019; shmilovm@mail.nih.gov.

High-Affinity Dopamine D3 Receptor Antagonists and Partial Agonists

Description of Technology: Investigators at the National Institute on Drug Abuse (NIDA) have synthesized a novel class of dopamine D3 receptor ligands using click chemistry. These novel compounds contain a triazole instead of an amide group between the primary and secondary pharmacophore. Although the amide linker has been shown to be essential for high affinity and selectivity in certain D3 receptor ligands, NIDA investigators have determined that the triazole linker maintains desired D3 receptor-binding functionality, and may improve bioavailability because of its resistance to metabolic amidases.

Potential Commercial Applications:

- Therapeutic agent for substance abuse (such as alcohol, nicotine, cocaine, methamphetamine, opioids)
- Therapeutic agent for cognitive disorders (such as schizophrenia, Parkinson’s disease, dyskinesia, depression)
- Therapeutic agent for restless legs syndrome

Competitive Advantages:

- Higher affinity for the dopamine D3 receptor
- Improved bioavailability

Development Stage: Early-stage.


Related Technologies:

- HHS Reference No. E–251–2002—US Provisional Application No. 60/410,715

Licensing Contact: Charlene Sydnor, Ph.D.; 301–435–4689; sydnorc@mail.nih.gov.

Collaborative Research Opportunity: The National Institute on Drug Abuse is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize D3 receptor selective antagonists/agonists. For collaboration opportunities, please contact Michelle Kim Leff, MD, MBA at mleff@mail.nih.gov.